NCT06281847
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 31, 2025
Completion: Aug 31, 2041